-+ 0.00%
-+ 0.00%
-+ 0.00%

Invivyd's VMS063 shows potent activity against measles variants in lab tests

PUBT·10/21/2026 11:06:54
Listen to the news
Invivyd's VMS063 shows potent activity against measles variants in lab tests
  • Invivyd presented preclinical data at IDWeek 2026 showing potent laboratory antiviral activity for its investigational measles antibody VMS063.
  • Testing covered historical and contemporary measles variants, including B3 and D8, supporting potential use for treatment and prevention.
  • Manufacturing scale-up has begun toward clinical development in 2027, with intramuscular or subcutaneous formulations planned.
  • No FDA-approved measles treatments currently exist.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210701PRIMZONEFULLFEED9850019) on October 21, 2026, and is solely responsible for the information contained therein.